Technology Appraisal Guidance No. 118
Source: National Institute for Health and Care Excellence
This guidance has been partially updated by 'Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy' (NICE technology appraisal guidance 242) [TA242]. The recommendation that has been updated is indicated in section 1 below. See TA242 (www.nice.org.uk/guidance/TA242) for details of the new recommendations and evidence considered.
1.1 Bevacizumab in combination with 5-fluorouracil plus folinic acid, with or without irinotecan, is not recommended for the first-line treatment of metastatic colorectal cancer.
1.2 This recommendation has been updated and replaced by NICE Technology appraisal guidence 242.
1.3 People currently receiving bevacizumab or cetuximab should have the option to continue therapy until they and their consultants consider it appropriate to stop.
The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA118
An abridged version of this guidance (a 'quick reference guide') is also available. Printed copies of the quick reference guide can be obtained by contacting 0845 003 7783 or emailing email@example.com and quoting reference number N1199. It is also available on the Internet at http://guidance.nice.org.uk/TA118/quickrefguide/pdf/English
This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: firstname.lastname@example.org
Bevacizumab and Cetuximab for the Treatment of Metastatic Colorectal Cancer.
Issue Date: January 2007
Review Date: May 2009